• Skip to primary navigation
  • Skip to main content
  • Skip to footer
  • Skip to investors navigation
Insmed

Insmed

Powered by Purpose

LinkedIn Twitter Contact Us Job Opportunities

  • Culture
    • Our Culture
      • Mission & Vision
      • Careers
      • Responsibility
        • Inclusion at Insmed
        • Grants & Funding
        • Global Healthcare Compliance

    Our Global Company

    Find available career opportunities in the U.S., Japan, or Europe.

    Find Jobs

  • Patients
    • Our Patients
      • Disease Areas
      • Resources
      • Patient Access

    Current Clinical Trials

    You may be eligible for one of our clinical trials.

    See if you may qualify

  • Science
    • Our Science
      • Our Pillars
        • ARIKAYCE®
        • Brensocatib
        • TPIP
        • Early-Stage Research
      • Pipeline
      • Clinical Trials
      • Investigator-Initiated Research

    Our Research

    Working together to develop new medicines and technologies that have the potential to transform patients’ lives.

    Learn More

  • About
    • About Insmed
    • Management Team
    • Board of Directors
    • Partnerships
  • Investors
    • Investors
    • Events & Presentations
    • Stock Information
    • News Releases
    • SEC Filings
    • Annual Reports
    • Analyst Coverage
    • Corporate Governance
    • Email Alerts
    • Investor FAQs
Home / About / Management Team / Drayton Wise

Drayton Wise

Chief Commercial Officer

Drayton joined Insmed in 2014 and has served as SVP, Head of U.S. and General Manager of the ARIKAYCE global program. He became Chief Commercial Officer in May 2022, bringing more than 20 years of pharmaceutical industry leadership experience to the role. During his tenure at Insmed, he has been instrumental in successfully building the U.S. commercial organization, including its capabilities, infrastructure, and team. These efforts contributed to the launch of the Company’s first commercial product in the U.S., ARIKAYCE, which became one of the top 10 most successful non-oncology rare disease launches. Prior to Insmed, Drayton worked for Novartis in positions of increasing responsibility, including National Director, Cystic Fibrosis Sales & Account Management, and Head, Strategy and Operations for the Respiratory Business Unit, a ~$1 billion multi-product specialty business unit. While at Novartis, he contributed to the launch of 14 products across multiple diseases states, and in the role of National Director, his team was responsible for the highly successful launch of TOBI Podhaler. Drayton is passionate about improving patient outcomes, developing culture and talent, building diverse teams to achieve exceptional results, and fostering deep relationships in the KOL and advocacy communities. He is a graduate of The Citadel and holds a Master of Business Administration from Emory University.

Prev
Return to management team
Next

Footer

Insmed
LinkedInTwitter

Contact Us

Job Opportunities

  • Our Culture
    • Mission & Vision
    • Careers
    • Responsibility
      • Inclusion at Insmed
      • Grants & Funding
      • Global Healthcare Compliance
  • Our Patients
    • Disease Areas
    • Resources
    • Patient Access
  • Our Science
    • Our Pillars
      • ARIKAYCE®
      • Brensocatib
      • TPIP
      • Early-Stage Research
    • Pipeline
    • Clinical Trials
    • Investigator-Initiated Research
  • About
    • Management Team
    • Board of Directors
    • Partnerships
  • Investors
  • Events & Presentations
  • Stock Information
  • News Releases
  • SEC Filings
  • Annual Reports
  • Analyst Coverage
  • Corporate Governance
  • Email Alerts
  • Investor FAQs

© 2022 Insmed Incorporated. All Rights Reserved. Terms of Use Privacy Policy

Culture
Patients
Science
logo
  • Culture
    • Mission & Vision
    • Careers
    • Responsibility
      • Inclusion at Insmed
      • Grants & Funding
      • Global Healthcare Compliance
  • Patients
    • Disease Areas
    • Resources
    • Patient Access
  • Science
    • Our Pillars
      • ARIKAYCE®
      • Brensocatib
      • TPIP
      • Early-Stage Research
    • Pipeline
    • Clinical Trials
    • Investigator-Initiated Research
  • About
    • Management Team
    • Board of Directors
    • Partnerships
  • Investors
    • Events & Presentations
    • Stock Information
    • News Releases
    • SEC Filiings
    • Annual Reports
    • Analyst Coverage
    • Corporate Governance
    • Email Alerts
    • Investor FAQs

LinkedIn Twitter

Contact Us Job Opportunities

© 2021 Insmed Incorporated.
All Rights Reserved.

Terms of Use Privacy Policy

Cookie Policy

Effective February 15, 2022, we have modified our Privacy Policy. Please read these updated terms and take some time to understand them. This website, as well as certain third parties that provide content, other functionality, or services to this site, may use Internet technologies to collect information. These technologies include cookies, local stored objects, web beacons, and other means. By using this site, you consent to our use of such cookies and similar technologies.
Accept